. Author manuscript; available in PMC: 2017 Aug 1.

Published in final edited form as: Biochim Biophys Acta. 2016 Feb 26;1860(8):1615–1622. doi: 10.1016/j.bbagen.2016.02.015

Table 2.

Glycosylation research in autoimmune diseases mimicked by cGVHD.

Author ^reference/year	Disease^*	Key findings of the study
Dry mouth and eye disorders
P. Youinou et al⁸⁰/1992	Sjögren’s syndrome	Elevated levels of asialylated IgG.
I. Castro et al⁸¹/2013	Sjögren’s syndrome	Altered salivary mucins.
Gastrointestinal disorders
J. M. H. Larsson et al⁸⁵/2011	IBD	Reduced glycosylation of gastrointestinal mucins.
A. M. Dias et al⁸⁷/2013	IBD	Aberrant N-glycosylation of T cell receptor.
I. Trbojevic Akmacic et al²³/2015	IBD	Reduced immunosuppressive potential of IgG in IBD.
Hematological disorders
T. Bakchoul et al⁹²/2013	ITP	N-glycosylation of AAbs suggested to be prerequisite for platelet phagocytosis in vitro and in vivo.
Neurological and muscular disorders
M. H. J. Selman et al⁹⁴/2011	Myasthenia gravis	Lower levels of IgG2 galactosylation.
I. Perdivara et al⁹⁵/2011	Myositis	Lower levels of IgG galactosylation.
Other
C. Panzironi et al⁸³/1997	SLE	‘Incresead carbohydrate moiety’ and higher concentration of galactose in α2-macroglobulin.
X.-X. Chen et al⁸⁴/2015	SLE	Reduced IgG sialylation.
F. Vuckovic et al²⁴/2015	SLE	Reduced immunosuppressive potential of IgG.

IBD=inflammatory bowel disease; ITP= immune thrombocytopenia; SLE= systemic lupus erythematosus